Roivant Sciences (ROIV) — insider trading
Health Care · NASDAQ
Roivant Sciences (ROIV) has 124 reported SEC Form 4 insider transactions in our data, including 39 open-market sales among the most recent 100 (latest 2026-10-01).
Recent Form 4 transactions
Showing the 100 most recent of 124 recorded transactions. See all on SEC EDGAR →
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Epperly Melissa B, | Director | Option exercise / conversion (derivative) | 17,750 | — | $0 | Form 4 |
| 2026-10-01 | Epperly Melissa B, | Director | Open-market sale | 900 | $36.57 | $32.9K | Form 4 |
| 2026-10-01 | Epperly Melissa B, | Director | Open-market sale | 16,850 | $36.08 | $607.9K | Form 4 |
| 2026-10-01 | Epperly Melissa B, | Director | Option exercise / conversion | 17,750 | $4.46 | $79.2K | Form 4 |
| 2026-09-30 | Sukhatme Mayukh | Director, Officer (President & CIO) | Shares withheld for taxes / exercise cost | 46,879 | $36.57 | $1.71M | Form 4 |
| 2026-09-30 | Venker Eric | Officer (President & Immunovant CEO) | Option exercise / conversion (derivative) | 200,000 | — | $0 | Form 4 |
| 2026-09-30 | Venker Eric | Officer (President & Immunovant CEO) | Open-market sale | 200,000 | $36.62 | $7.32M | Form 4 |
| 2026-09-30 | Venker Eric | Officer (President & Immunovant CEO) | Option exercise / conversion | 200,000 | $3.85 | $770.0K | Form 4 |
| 2026-09-30 | Torti Frank | Officer (President and Vant Chair) | Shares withheld for taxes / exercise cost | 40,309 | $36.57 | $1.47M | Form 4 |
| 2026-09-30 | Gline Matthew | Director, Officer (CEO) | Shares withheld for taxes / exercise cost | 76,171 | $36.57 | $2.79M | Form 4 |
| 2026-09-20 | Pulik Richard | Officer (CFO) | Shares withheld for taxes / exercise cost | 2,129 | $39.77 | $84.7K | Form 4 |
| 2026-09-20 | Humes Jennifer | Officer (Chief Accounting Officer) | Shares withheld for taxes / exercise cost | 3,880 | $39.77 | $154.3K | Form 4 |
| 2026-09-16 | Oren Ilan | Director | Grant / award / vesting (derivative) | 10,531 | — | $0 | Form 4 |
| 2026-09-16 | Oren Ilan | Director | Grant / award / vesting | 5,054 | — | $0 | Form 4 |
| 2026-09-16 | MOMTAZEE JAMES C | Director | Grant / award / vesting (derivative) | 10,531 | — | $0 | Form 4 |
| 2026-09-16 | MOMTAZEE JAMES C | Director | Grant / award / vesting | 5,054 | — | $0 | Form 4 |
| 2026-09-16 | MANCHESTER KEITH S | Director | Grant / award / vesting (derivative) | 10,531 | — | $0 | Form 4 |
| 2026-09-16 | MANCHESTER KEITH S | Director | Grant / award / vesting | 5,054 | — | $0 | Form 4 |
| 2026-09-16 | Gold Daniel Allen | Director | Grant / award / vesting (derivative) | 10,531 | — | $0 | Form 4 |
| 2026-09-16 | Gold Daniel Allen | Director | Grant / award / vesting | 5,054 | — | $0 | Form 4 |
| 2026-09-16 | Fitzgerald Meghan | Director | Grant / award / vesting (derivative) | 10,531 | — | $0 | Form 4 |
| 2026-09-16 | Fitzgerald Meghan | Director | Grant / award / vesting | 5,054 | — | $0 | Form 4 |
| 2026-09-16 | Epperly Melissa B, | Director | Grant / award / vesting (derivative) | 10,531 | — | $0 | Form 4 |
| 2026-09-16 | Epperly Melissa B, | Director | Grant / award / vesting | 5,054 | — | $0 | Form 4 |
| 2026-09-15 | Fitzgerald Meghan | Director | Open-market sale | 400 | $40.45 | $16.2K | Form 4 |
| 2026-09-15 | Fitzgerald Meghan | Director | Open-market sale | 4,712 | $39.68 | $187.0K | Form 4 |
| 2026-09-15 | Epperly Melissa B, | Director | Open-market sale | 600 | $40.38 | $24.2K | Form 4 |
| 2026-09-15 | Epperly Melissa B, | Director | Open-market sale | 4,338 | $39.65 | $172.0K | Form 4 |
| 2026-09-10 | Oren Ilan | Director | Shares withheld for taxes / exercise cost | 2,378 | $40.94 | $97.4K | Form 4 |
| 2026-09-10 | MOMTAZEE JAMES C | Director | Shares withheld for taxes / exercise cost | 2,905 | $40.94 | $118.9K | Form 4 |
| 2026-09-10 | Gold Daniel Allen | Director | Shares withheld for taxes / exercise cost | 5,133 | $40.94 | $210.1K | Form 4 |
| 2026-09-10 | Fitzgerald Meghan | Director | Shares withheld for taxes / exercise cost | 1,743 | $40.94 | $71.4K | Form 4 |
| 2026-09-10 | Epperly Melissa B, | Director | Shares withheld for taxes / exercise cost | 2,179 | $40.94 | $89.2K | Form 4 |
| 2026-09-08 | Fitzgerald Meghan | Director | Option exercise / conversion (derivative) | 20,000 | — | $0 | Form 4 |
| 2026-09-08 | Fitzgerald Meghan | Director | Open-market sale | 20,000 | $39.90 | $798.0K | Form 4 |
| 2026-09-08 | Fitzgerald Meghan | Director | Option exercise / conversion | 20,000 | $8.80 | $176.0K | Form 4 |
| 2026-08-28 | Venker Eric | Officer (President & Immunovant CEO) | Option exercise / conversion (derivative) | 200,000 | — | $0 | Form 4 |
| 2026-08-28 | Venker Eric | Officer (President & Immunovant CEO) | Open-market sale | 33,818 | $36.44 | $1.23M | Form 4 |
| 2026-08-28 | Venker Eric | Officer (President & Immunovant CEO) | Open-market sale | 166,182 | $35.63 | $5.92M | Form 4 |
| 2026-08-28 | Venker Eric | Officer (President & Immunovant CEO) | Option exercise / conversion | 200,000 | $3.85 | $770.0K | Form 4 |
| 2026-08-21 | Sukhatme Mayukh | Director, Officer (President & CIO) | Option exercise / conversion (derivative) | 144,756 | — | $0 | Form 4 |
| 2026-08-21 | Sukhatme Mayukh | Director, Officer (President & CIO) | Open-market sale | 144,756 | $36.48 | $5.28M | Form 4 |
| 2026-08-21 | Sukhatme Mayukh | Director, Officer (President & CIO) | Option exercise / conversion | 144,756 | $3.85 | $557.3K | Form 4 |
| 2026-08-20 | Venker Eric | Officer (President & Immunovant CEO) | Shares withheld for taxes / exercise cost | 13,909 | $36.84 | $512.4K | Form 4 |
| 2026-08-20 | Pulik Richard | Officer (CFO) | Shares withheld for taxes / exercise cost | 5,749 | $36.84 | $211.8K | Form 4 |
| 2026-08-20 | Sukhatme Mayukh | Director, Officer (President & CIO) | Option exercise / conversion (derivative) | 17,519 | — | $0 | Form 4 |
| 2026-08-20 | Sukhatme Mayukh | Director, Officer (President & CIO) | Open-market sale | 17,519 | $37.30 | $653.5K | Form 4 |
| 2026-08-20 | Sukhatme Mayukh | Director, Officer (President & CIO) | Option exercise / conversion | 17,519 | $3.85 | $67.4K | Form 4 |
| 2026-08-19 | Sukhatme Mayukh | Director, Officer (President & CIO) | Option exercise / conversion (derivative) | 172,899 | — | $0 | Form 4 |
| 2026-08-19 | Sukhatme Mayukh | Director, Officer (President & CIO) | Open-market sale | 172,899 | $37.17 | $6.43M | Form 4 |
| 2026-08-19 | Sukhatme Mayukh | Director, Officer (President & CIO) | Option exercise / conversion | 172,899 | $3.85 | $665.7K | Form 4 |
| 2026-08-18 | Sukhatme Mayukh | Director, Officer (President & CIO) | Option exercise / conversion (derivative) | 136,942 | — | $0 | Form 4 |
| 2026-08-18 | Sukhatme Mayukh | Director, Officer (President & CIO) | Open-market sale | 31,801 | $37.18 | $1.18M | Form 4 |
| 2026-08-18 | Sukhatme Mayukh | Director, Officer (President & CIO) | Option exercise / conversion | 31,801 | $3.85 | $122.4K | Form 4 |
| 2026-08-18 | Sukhatme Mayukh | Director, Officer (President & CIO) | Open-market sale | 105,141 | $36.59 | $3.85M | Form 4 |
| 2026-08-18 | Sukhatme Mayukh | Director, Officer (President & CIO) | Option exercise / conversion | 105,141 | $3.85 | $404.8K | Form 4 |
| 2026-08-17 | Sukhatme Mayukh | Director, Officer (President & CIO) | Option exercise / conversion (derivative) | 284,707 | — | $0 | Form 4 |
| 2026-08-17 | Sukhatme Mayukh | Director, Officer (President & CIO) | Open-market sale | 284,707 | $36.25 | $10.32M | Form 4 |
| 2026-08-17 | Sukhatme Mayukh | Director, Officer (President & CIO) | Option exercise / conversion | 284,707 | $3.85 | $1.10M | Form 4 |
| 2026-08-14 | Sukhatme Mayukh | Director, Officer (President & CIO) | Option exercise / conversion (derivative) | 243,177 | — | $0 | Form 4 |
| 2026-08-14 | Sukhatme Mayukh | Director, Officer (President & CIO) | Open-market sale | 243,177 | $36.23 | $8.81M | Form 4 |
| 2026-08-14 | Sukhatme Mayukh | Director, Officer (President & CIO) | Option exercise / conversion | 243,177 | $3.85 | $936.2K | Form 4 |
| 2026-07-27 | Venker Eric | Officer (President & Immunovant CEO) | Option exercise / conversion (derivative) | 200,000 | — | $0 | Form 4 |
| 2026-07-27 | Venker Eric | Officer (President & Immunovant CEO) | Open-market sale | 200,000 | $34.95 | $6.99M | Form 4 |
| 2026-07-27 | Venker Eric | Officer (President & Immunovant CEO) | Option exercise / conversion | 200,000 | $3.85 | $770.0K | Form 4 |
| 2026-07-17 | Oren Ilan | Director | Grant / award / vesting | 775 | — | $0 | Form 4 |
| 2026-07-17 | Epperly Melissa B, | Director | Grant / award / vesting | 543 | — | $0 | Form 4 |
| 2026-07-17 | MOMTAZEE JAMES C | Director | Grant / award / vesting | 405 | — | $0 | Form 4 |
| 2026-06-30 | Sukhatme Mayukh | Director, Officer (President & CIO) | Shares withheld for taxes / exercise cost | 46,878 | $35.39 | $1.66M | Form 4 |
| 2026-06-30 | Torti Frank | Officer (President and Vant Chair) | Shares withheld for taxes / exercise cost | 40,310 | $35.39 | $1.43M | Form 4 |
| 2026-06-30 | Fitzgerald Meghan | Director | Option exercise / conversion (derivative) | 10,000 | — | $0 | Form 4 |
| 2026-06-30 | Fitzgerald Meghan | Director | Open-market sale | 10,000 | $34.90 | $349.0K | Form 4 |
| 2026-06-30 | Fitzgerald Meghan | Director | Option exercise / conversion | 10,000 | $8.80 | $88.0K | Form 4 |
| 2026-06-30 | Gline Matthew | Director, Officer (CEO) | Shares withheld for taxes / exercise cost | 76,171 | $35.39 | $2.70M | Form 4 |
| 2026-06-30 | QVT Financial LP | Other | Open-market sale | 12,380 | $35.28 | $436.8K | Form 4 |
| 2026-06-30 | Gold Daniel Allen | Director | Open-market sale | 12,380 | $35.28 | $436.8K | Form 4 |
| 2026-06-30 | MANCHESTER KEITH S | Director | Open-market sale | 200,000 | $35.45 | $7.09M | Form 4 |
| 2026-06-30 | MANCHESTER KEITH S | Director | Open-market sale | 12,380 | $35.28 | $436.8K | Form 4 |
| 2026-06-29 | Epperly Melissa B, | Director | Option exercise / conversion (derivative) | 17,750 | — | $0 | Form 4 |
| 2026-06-29 | Epperly Melissa B, | Director | Open-market sale | 2,748 | $34.71 | $95.4K | Form 4 |
| 2026-06-29 | Epperly Melissa B, | Director | Open-market sale | 15,002 | $34.32 | $514.9K | Form 4 |
| 2026-06-29 | Epperly Melissa B, | Director | Option exercise / conversion | 17,750 | $4.46 | $79.2K | Form 4 |
| 2026-06-29 | QVT Financial LP | Other | Open-market sale | 600,000 | $34.59 | $20.75M | Form 4 |
| 2026-06-29 | QVT Financial LP | Other | Open-market sale | 200,000 | $34.44 | $6.89M | Form 4 |
| 2026-06-29 | Gold Daniel Allen | Director | Open-market sale | 600,000 | $34.59 | $20.75M | Form 4 |
| 2026-06-29 | Gold Daniel Allen | Director | Open-market sale | 200,000 | $34.44 | $6.89M | Form 4 |
| 2026-06-29 | MANCHESTER KEITH S | Director | Open-market sale | 600,000 | $34.59 | $20.75M | Form 4 |
| 2026-06-29 | MANCHESTER KEITH S | Director | Open-market sale | 200,000 | $34.44 | $6.89M | Form 4 |
| 2026-06-26 | QVT Financial LP | Other | Open-market sale | 325,000 | $34.07 | $11.07M | Form 4 |
| 2026-06-26 | QVT Financial LP | Other | Open-market sale | 300,783 | $33.92 | $10.20M | Form 4 |
| 2026-06-26 | Gold Daniel Allen | Director | Open-market sale | 325,000 | $34.07 | $11.07M | Form 4 |
| 2026-06-26 | Gold Daniel Allen | Director | Open-market sale | 300,783 | $33.92 | $10.20M | Form 4 |
| 2026-06-26 | MANCHESTER KEITH S | Director | Open-market sale | 325,000 | $34.07 | $11.07M | Form 4 |
| 2026-06-26 | MANCHESTER KEITH S | Director | Open-market sale | 300,783 | $33.92 | $10.20M | Form 4 |
| 2026-06-26 | Sukhatme Mayukh | Director, Officer (President & CIO) | Option exercise / conversion (derivative) | 500,000 | — | $0 | Form 4 |
| 2026-06-26 | Sukhatme Mayukh | Director, Officer (President & CIO) | Open-market sale | 500,000 | $34.08 | $17.04M | Form 4 |
| 2026-06-26 | Sukhatme Mayukh | Director, Officer (President & CIO) | Option exercise / conversion | 500,000 | $3.85 | $1.93M | Form 4 |
| 2026-06-25 | Sukhatme Mayukh | Director, Officer (President & CIO) | Option exercise / conversion (derivative) | 500,000 | — | $0 | Form 4 |
| 2026-06-25 | Sukhatme Mayukh | Director, Officer (President & CIO) | Open-market sale | 500,000 | $34.13 | $17.07M | Form 4 |
| 2026-06-25 | Sukhatme Mayukh | Director, Officer (President & CIO) | Option exercise / conversion | 500,000 | $3.85 | $1.93M | Form 4 |
Ask the chat about ROIV's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Roivant Sciences (ROIV).
Last updated 2026-10-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.